{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:07Z","timestamp":1794047347465,"version":"4.8.0"},"reference-count":45,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Disruption of the normal splicing patterns of RNA is a major factor in the pathogenesis of a number of diseases. Increasingly research has shown the strong influence that splicing patterns can have on cancer progression. Multiple Myeloma is a molecularly heterogeneous disease classified by the presence of key translocations, gene expression profiles and mutations but the splicing patterns in MM remains largely unexplored. We take a multifaceted approach to define the extent and impact of alternative splicing in MM. We look at the spliceosome component, SF3B1, with hotspot mutations (K700E and K666T\/Q) shown to result in an increase in alternative splicing in other cancers. We discovered a number of differentially spliced genes in comparison of the SF3B1 mutant and wild type samples that included, MZB1, DYNLL1, TMEM14C and splicing related genes DHX9, CLASRP, and SNRPE. We identified a broader role for abnormal splicing showing clear differences in the extent of novel splice variants in the different translocation groups. We show that a high number of novel splice loci is associated with adverse survival and an ultra-high risk group. The enumeration of patterns of alternative splicing has the potential to refine MM classification and to aid in the risk stratification of patients.<\/jats:p>","DOI":"10.3324\/haematol.2019.235424","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:15:24Z","timestamp":1582197324000},"page":"736-745","source":"Crossref","is-referenced-by-count":32,"title":["Differential RNA splicing as a potentially important driver mechanism in multiple myeloma"],"prefix":"10.3324","volume":"106","author":[{"family":"Michael A. Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Cody Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Christopher Wardell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Eileen M. Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Maria Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Erin Flynt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anjan Thakurta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Gareth Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Brian A. Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"22253","doi-asserted-by":"crossref","unstructured":"Walker BA, Mavrommatis K, Wardell CP. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132(6):587-597.","DOI":"10.1182\/blood-2018-03-840132"},{"key":"22254","doi-asserted-by":"crossref","unstructured":"Prideaux SM, O\u2019Brien EC, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol. 2014; 2014:864058.","DOI":"10.1155\/2014\/864058"},{"key":"22255","doi-asserted-by":"crossref","unstructured":"Lee SC-W, Dvinge H, Kim E. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016; 22(6):672-678.","DOI":"10.1038\/nm.4097"},{"key":"22256","doi-asserted-by":"crossref","unstructured":"Urbanski LM, Leclair N, Anczuk\u00f3w O.. Alternative-splicing defects in cancer: splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley Interdiscip Rev RNA. 2018; 9(4):e1476.","DOI":"10.1002\/wrna.1476"},{"key":"22257","doi-asserted-by":"crossref","unstructured":"Li YI, van de Geijn B, Raj A. RNA splicing is a primary link between genetic variation and disease. Science. 2016; 352(6285):600-604.","DOI":"10.1126\/science.aad9417"},{"key":"22258","doi-asserted-by":"crossref","unstructured":"Climente-Gonz\u00e1lez H, Porta-Pardo E, Godzik A, Eyras E.. The functional impact of alternative splicing in cancer. Cell Rep. 2017; 20(9):2215-2226.","DOI":"10.1016\/j.celrep.2017.08.012"},{"key":"22259","doi-asserted-by":"crossref","unstructured":"Sebesty\u00e9n E, Singh B, Mi\u00f1ana B. Largescale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Res. 2016; 26(6):732-744.","DOI":"10.1101\/gr.199935.115"},{"key":"22260","doi-asserted-by":"crossref","unstructured":"Lee Y, Rio DC. Mechanisms and regulation of alternative pre-mRNA splicing. Annu Rev Biochem. 2015; 84(1):291-323.","DOI":"10.1146\/annurev-biochem-060614-034316"},{"key":"22261","doi-asserted-by":"crossref","unstructured":"Corvelo A, Hallegger M, Smith CWJ, Eyras E.. Genome-wide association between branch point properties and alternative splicing. PLoS Comput Biol. 2010; 6(11):e1001016.","DOI":"10.1371\/journal.pcbi.1001016"},{"key":"22262","doi-asserted-by":"crossref","unstructured":"Lin P-C, Xu R-M. Structure and assembly of the SF3a splicing factor complex of U2 snRNP. EMBO J. 2012; 31(6):1579-1590.","DOI":"10.1038\/emboj.2012.7"},{"key":"22263","doi-asserted-by":"crossref","unstructured":"Wang L, Brooks AN, Fan J. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. Cancer Cell. 2016; 30(5):750-763.","DOI":"10.1016\/j.ccell.2016.10.005"},{"key":"22264","doi-asserted-by":"crossref","unstructured":"DeBoever C, Ghia EM, Shepard PJ. Transcriptome sequencing reveals potential mechanism of cryptic 3\u2019 splice site selection in SF3B1-mutated cancers. PLOS Comput Biol. 2015; 11(3):e1004105.","DOI":"10.1371\/journal.pcbi.1004105"},{"key":"22265","doi-asserted-by":"crossref","unstructured":"Dolatshad H, Pellagatti A, Fernandez- Mercado M. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia. 2015; 29(5):1092-1103.","DOI":"10.1038\/leu.2014.331"},{"key":"22266","doi-asserted-by":"crossref","unstructured":"Inoue D, Abdel-Wahab O.. Modeling SF3B1 mutations in cancer: advances, challenges, and opportunities. Cancer Cell. 2016; 30(3):371-373.","DOI":"10.1016\/j.ccell.2016.08.013"},{"key":"22267","doi-asserted-by":"crossref","unstructured":"Furney SJ, Pedersen M, Gentien D. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013; 3(10):1122-1129.","DOI":"10.1158\/2159-8290.CD-13-0330"},{"key":"22268","doi-asserted-by":"crossref","unstructured":"Maguire SL, Leonidou A, Wai P. SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol. 2015; 235(4):571-580.","DOI":"10.1002\/path.4483"},{"key":"22269","doi-asserted-by":"crossref","unstructured":"Kesarwani AK, Ramirez O, Gupta AK. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3\u2019 splice sites within RNA secondary structures. Oncogene. 2017; 36(8):1123-1133.","DOI":"10.1038\/onc.2016.279"},{"key":"22270","doi-asserted-by":"crossref","unstructured":"Alsafadi S, Houy A, Battistella A. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016; 7:10615.","DOI":"10.1038\/ncomms10615"},{"key":"22271","doi-asserted-by":"crossref","unstructured":"Walker BA, Mavrommatis K, Wardell CP. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019; 33(1):159-170.","DOI":"10.1038\/s41375-018-0196-8"},{"key":"22272","doi-asserted-by":"crossref","unstructured":"Dobin A, Davis CA, Schlesinger F. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29(1):15-21.","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"22273","unstructured":"Patro R, Duggal G, Kingsford C.. Salmon: accurate, versatile and ultrafast quantification from RNA-seq data using lightweightalignment. bioRxiv. 2015;021592."},{"key":"22274","doi-asserted-by":"crossref","unstructured":"Hartley SW, Mullikin JC. QoRTs: a comprehensive toolset for quality control and data processing of RNA-Seq experiments. BMC Bioinformatics. 2015; 16(1):224.","DOI":"10.1186\/s12859-015-0670-5"},{"key":"22275","doi-asserted-by":"crossref","unstructured":"Hartley SW, Mullikin JC. Detection and visualization of differential splicing in RNASeq data with JunctionSeq. Nucleic Acids Res. 2016; 44(15):e127.","DOI":"10.1093\/nar\/gkw501"},{"key":"22276","unstructured":"Reyes A, Anders S, Huber W.. Analyzing RNA-seq data for differential exon usage with the DEXSeq package. Gastroenterology. 2011; 138(3):958-968."},{"key":"22277","unstructured":"Alamancos GP, Pag\u00e8s A, Trincado JL, Bellora N, Eyras E.. SUPPA: a super-fast pipeline for alternative splicing analysis from RNA-Seq. bioRxiv. 2014;008763."},{"key":"22278","doi-asserted-by":"crossref","unstructured":"Zhao J, Song X, Wang K.. lncScore: alignment- free identification of long noncoding RNA from assembled novel transcripts. Sci Rep. 2016; 6(1):34838.","DOI":"10.1038\/srep34838"},{"key":"22279","doi-asserted-by":"crossref","unstructured":"Riese DJ, Cullum RL. Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol. 2014; 28:49-56.","DOI":"10.1016\/j.semcdb.2014.03.005"},{"key":"22280","doi-asserted-by":"crossref","unstructured":"Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 2006; 4:48.","DOI":"10.1186\/1479-5876-4-48"},{"key":"22281","doi-asserted-by":"crossref","unstructured":"Huang M-Y, Xuan F, Liu W, Cui H-J. MINA controls proliferation and tumorigenesis of glioblastoma by epigenetically regulating cyclins and CDKs via H3K9me3 demethylation. Oncogene. 2017; 36(3):387-396.","DOI":"10.1038\/onc.2016.208"},{"key":"22282","doi-asserted-by":"crossref","unstructured":"Chen Y-IG, Moore RE, Ge HY, Young MK, Lee TD, Stevens SW. Proteomic analysis of in vivo-assembled pre-mRNA splicing complexes expands the catalog of participating factors. Nucleic Acids Res. 2007; 35(12):3928-3944.","DOI":"10.1093\/nar\/gkm347"},{"key":"22283","doi-asserted-by":"crossref","unstructured":"Hagiwara M. Alternative splicing: A new drug target of the post-genome era. Biochim Biophys Acta. 2005; 1754(1-2):324-331.","DOI":"10.1016\/j.bbapap.2005.09.010"},{"key":"22284","doi-asserted-by":"crossref","unstructured":"Chan CC, Dostie J, Diem MD. eIF4A3 is a novel component of the exon junction complex. RNA. 2004; 10(2):200-209.","DOI":"10.1261\/rna.5230104"},{"key":"22285","doi-asserted-by":"crossref","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P.. The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. 2015; 1(6):417-425.","DOI":"10.1016\/j.cels.2015.12.004"},{"key":"22286","doi-asserted-by":"crossref","unstructured":"Walker BA, Mavrommatis K, Wardell CP. A high-risk, double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019; 33(1):159-170.","DOI":"10.1038\/s41375-018-0196-8"},{"key":"22287","doi-asserted-by":"crossref","unstructured":"Pellagatti A, Armstrong RN, Steeples V. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations. Blood. 2018; 132(12):1225-1240.","DOI":"10.1182\/blood-2018-04-843771"},{"key":"22288","doi-asserted-by":"crossref","unstructured":"Yoshida K, Sanada M, Shiraishi Y. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64-69.","DOI":"10.1038\/nature10496"},{"key":"22289","doi-asserted-by":"crossref","unstructured":"Flach H, Rosenbaum M, Duchniewicz M. Mzb1 protein regulates calcium homeostasis, antibody secretion, and integrin activation in innate-like B cells. Immunity. 2010; 33(5):723-735.","DOI":"10.1016\/j.immuni.2010.11.013"},{"key":"22290","doi-asserted-by":"crossref","unstructured":"Rosenbaum M, Andreani V, Kapoor T. MZB1 is a GRP94 cochaperone that enables proper immunoglobulin heavy chain biosynthesis upon ER stress. Genes Dev. 2014; 28(11):1165-1178.","DOI":"10.1101\/gad.240762.114"},{"key":"22291","doi-asserted-by":"crossref","unstructured":"Herold T, Mulaw MA, Jurinovic V. High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. Leuk Lymphoma. 2013; 54(8):1652-1657.","DOI":"10.3109\/10428194.2012.753445"},{"key":"22292","doi-asserted-by":"crossref","unstructured":"Walter P, Ron D.. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011; 334(6059):1081-1086.","DOI":"10.1126\/science.1209038"},{"key":"22293","doi-asserted-by":"crossref","unstructured":"Lin JH, Li H, Yasumura D. IRE1 Signaling affects cell fate during the unfolded protein response. Science. 2007; 318(5852):944-949.","DOI":"10.1126\/science.1146361"},{"key":"22294","doi-asserted-by":"crossref","unstructured":"Walker BA, Mavrommatis K, Wardell CP. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132(6):587-597.","DOI":"10.1182\/blood-2018-03-840132"},{"key":"22295","doi-asserted-by":"crossref","unstructured":"Obeng EA, Chappell RJ, Seiler M. Physiologic expression of Sf3b1K700E causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell. 2016; 30(3):404-417.","DOI":"10.1016\/j.ccell.2016.08.006"},{"key":"22296","doi-asserted-by":"crossref","unstructured":"Seiler M, Yoshimi A, Darman R. H3B- 8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018; 24(4):497-504.","DOI":"10.1038\/nm.4493"},{"key":"22297","doi-asserted-by":"crossref","unstructured":"Huang HH-L, Ferguson ID, Thornton AM. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. bioRxiv. 2018;508549.","DOI":"10.1101\/508549"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9667\/70622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9667\/70623","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9667\/70622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:56:09Z","timestamp":1794045369000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.235424","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,20]]}}}